Casgevy gains FDA pediatric approval, boosting Crispr Therapeutics' market and stock to 4-month high.

Crispr Therapeutics received FDA approval for Casgevy in pediatric patients, expanding its potential market and reinforcing its leadership in gene editing. Despite initial slow sales due to treatment complexity and cost, Casgevy's strong clinical results and safety profile support its multibillion-dollar potential. The company’s pipeline includes innovative gene therapies targeting cardiovascular and autoimmune diseases, aiming to simplify treatments further. This approval is expected to accelerate revenue growth and could drive Crispr's stock toward historic highs.